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INTRODUCTION

I
n penetrating keratoplasty (PK) in high risk patients, even with current immunosuppression, rejection rates can be over 70%, whereas PK in normal risk patients maintains the survival rates as high as 90% at the first year [1] [2] [3] [4] . Compared to normal risk penetrating keratoplasty (NRPK), eyes with high risk penetrating keratoplasty (HRPK) exhibited much higher levels of (lymph) angiogenesis [2] [3] [4] and inflammatory chemokines in early postoperative period [3, 5] . Risk for graft rejection can be corneal (lymph) angiogenesis, regrafts, high intraocular pressure, trauma, and perioperative inflammation. Corneal (lymph) angiogenesis is a well known risk for graft rejection and failure [3, 5] . Therefore, minimizing corneal (lymph) angiogenesis has the potential to decrease immunologic graft rejection and graft failure rates [6] [7] . Several anti-(lymph) angiognenic treatment was tried to enhance graft survival [7] [8] . However, because lymphatics might play important roles to heal conjunctivitis or conjunctivalchemosis or probable corneal edema, anti-lymphangiogenesis (LY) treatment can affect the wound healing of these structures [9] [10] . For example, rapamycin which can inhibit LY through inhibition of vascular endothelial growth factor (VEGF)-C can inhibit wound healing, even though its therapeutic effect for treatment of malignancy [10] . Especially in corneal transplantation, LY, not hemangiogenesis has been reported to be a primary mediator of rejection [7] [8] .
So, treatment targeting LY have been studied and developed to treat different tumors and ocular diseases. However, the other report showed that anti-angiogenic treatment such as strong VEGF-A trap was more successful in improving longterm graft survival as compared with anti-lymphangiogenic treatment such as anti VEGF-C and soluble vascular endothelial growth factor receptor (VEGFR) 3 [11] . The strong angiogenic VEGF-A increase hemangiogenesis through VEGFR-2 binding. The strong lymphangiogenic VEGF-C and -D are the main prolymphangiogenic factors that act through the activation of VEGFR-3 [8, 12] . When VEGF binds to VEGFR (receptor), then activation of the rat sarcom (RAS)/rapidly accelerated fibrosacrcoma (RAF)/extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK) starts signal transduction which leads to endothelial proliferation [8, 12] . Sorafenib is a potent inhibitor of RAS/RAF kinase and tyrosine kinases such as VEGFR-2, PDGFR β, and VEGFR-3 [12] [13] [14] . This multikinase inhibitors interfere with the activation of VEGFRs by preventing phosphorylation. Sorafenib is already in use as an anticancer drug that aims at tumor proliferation and neovascularization (NV) [12] [13] [14] . Recent reports have suggested new therapeutic role of sorafenib in ocular disease; age-related macular degeneration (AMD) and retinopathy of prematurity (ROP) [15] [16] . The effect of oral administration of sorafenib on choroidal and corneal NV was previously reported [17] . From the several previous reports of the effect of sorafenib in various type of tumor and neovascular disease in retina, we expected that sorafenib would work on cornea. We tried to evaluate the effect of sorafenib in neovascular disease of cornea, the HRPK, which has high graft failure rate due to severe hem/LY. Here, we studied the effect of subconjunctivally injected sorafenib on the graft survival, LY and hemangiogenesis in a mouse model of high risk corneal PK. ) and xylazine (10 mg/kg) was done. Prior to PK, two corneal sutures (10-0 nylon, CS140-6, Ethicon, Inc.) were placed between the corneal center and the limbus to induce vascularization. The corneal sutures were removed and corneal transplantation was done according to the methods used in the normal risk PK [18] .
SUBJETCS AND METHODS
Subconjunctival Injection of Anti-angiogenic Agents
Sorafenib (Santa Cruz Biotechnolology, Inc., Santa Cruz, CA, USA) was dialted with vehicle dimethyl sulfoxide (DMSO). In four group, the respective treatment; sorafenib (15 μL, 465 μg/mL, 12 eyes), dexamethasone (15 μL, 500 μg/mL, 12 eyes), DMSO (15 μL, 12 eyes) and phosphate buffered saline (PBS) (15 μL, 12 eyes) were injected into the subconjunctival space from the day of transplantation and weekly to postoperative 8wk. Among these groups, sorafenib group was the case group. And the dexamethasone, which is already known as antiangiogenic agent was the positive control group. The sorafenib was diluted with vehicle DMSO, so the DMSO was the negative control. PBS group was another negative control group. Clinical Evaluation of Rejection Microscopic examination was done weekly through post-op week 8 and corneal microscopic pictures were taken. Evaluation of graft clarity according to the grading system was done as previously described. The opacity grading (0 to 5) was as a previous report [19] : grades 3 and above were considered a graft rejection.
Analysis of Angiogenesis and Lymphangiogenesis
To know the extent of corneal NV and LY in the recipient cornea before grafting, two corneal sutures were placed on 6 corneas between the corneal center and the limbus. After two weeks, we harvested 6 corneas to evaluate the extent of corneal NV before grafting. After immune staing with CD31 and LYVE-1, we evaluated the extent of NV and LY under fluorescent microscope. After PK and the planned injections for observation periods (8wk after PK), we harvested eyes and the corneas were trimmed. Vascular and lymphatic endothelial cells were immunestained on corneal flat mounts as our previous report [20] . After immune staining and flat mounting of the cornea, images of the corneal vasculature were captured by a fluorescent microscope (OLYMPUS BX51, Tokyo, Japan). NV and LY were quantified as a previous report [20] . Total NV (%)=neovascularized area/total cornea area×100%; total LY (%)=LY area/total cornea area×100%.
Comparison of Graft Survival, Angiogenesis and Lymphangiogenesis in High Risk Penetrating Keratoplasty
The four groups (sorafenib, dexamethasone, DMSO and PBS) were compared in HRPK. Graft survival, NV and LY were compared. Quantitative Real-time Polymerase Chain Reaction Analysis of Gene Expression in the Mouse Cornea After harvesting, the corneas were trimmed and the expression of VEGF-A, VEGF-C, VEGFR-2, VEGFR-3, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 was analyzed using real-time polymerase chain reaction (RT-PCR) as previous report [20] . We used published primer sequences for mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [20] , VEGF-A [21] , VEGF-C [21] , VEGFR2 [21] , VEGFR3 [21] , TNF-alpha [22] , and IL-6 [23] . Each gene expression level was analyzed by the Ct method, using GAPDH expression as an internal control. The relative expression level of each sample is expressed as a fold change compared to the normal control (PBS). Statistical Analysis SPSS 11.5 (Chicago, IL, USA) was used. Graft survival was analyzed using Kaplan-Meier survival curves (log rank test (Figures 2, 3) . The dexamethasone group showed less LY compared to the DMSO and PBS group (P=0.035, 0.043, respectively). There was no difference of LY between DMSO and PBS. Sorafenib has significant anti-LY effect on cornea compared with dexamethasone, DMSO and PBS. 
DISCUSSION
Among human transplantation surgeries, corneal transplantation is one of the most commonly performed. The overall 10-year survival rates of corneal grafts reach between 75% and 80% [1] [2] [3] 5] . However, in the "high-risk" conditions, the survival rate drops to 30%-50% at 3 to 5-year followup [2, 11, 24] . Compared to normal risk keratoplasty, eyes with HRPK exhibited significantly higher levels of NV, LY [25] and inflammation in the early postoperative period [3, 5, [25] [26] .
The chemokines expressed in high risk eyes correlated with increased number of inflammatory cells in high risk recipients [26] . In this study, IL-6 and TNF-alpha, the inflammatory cytokines were significantly decreased by sorafenib as effectively as dexamethasone, even in HRPK which is different from normal risk PK in respect to their postoperative NV and inflammation. The most common possible reason for graft failure is immunologic rejection. The conditions that may place the cornea at a higher risk of rejection are corneal NV, LY, position of the graft close to limbus, and herpes simplex keratitis [5, 27] . It has been reported that the preexisting blood and lymphatic vessels in cornea is a strong risk factor for immune rejection [28] [29] . Ocular immune privilege can be acquired through avascularity, alymphatics, low major histocompatibility complex and native immunosuppression [3, 5] . Although the normal cornea does not have blood and lymphatic vessels, NV and LY can be induced after traumatic, chemical, inflammatory or infectious damage. LY especially constitutes the afferent arm of the corneal transplantation immunity, and recently, it has been demonstrated that LY is a primary mediator of corneal transplant rejection [8, 30] . So, decreasing lymphangiognesis can enhance graft survival. The VEGF is the a complex network controlling blood and lymphatic vessels [31] [32] [33] . Several previous studies have shown that VEGFR-3 mediates LY in the cornea and other tissues [34] [35] . Most recently, it has been indicated that VEGFR-2 also plays a role in corneal LY, but with unknown mechanism [30, [34] [35] . Our study evaluated the anti-angiognenic and antilymphangiogenic effect of sorafenib, as a therapeutic option against graft rejection in high risk keratoplasty. Sorafenib, a multikinase inhibitor, has shown promising results for the treatment of advanced hepatocellular carcinoma in clinical trials. The mechanisms of sorafenib's antitumor activities have been well presented. Evidence has shown that sorafenib inhibits the rapidly accelerated RAF/ MAPK/ERK kinase (MEK)/ERK signal pathways and receptor tyrosine kinases, including VEGFR-2, VEGFR-3, Flt-3, c-KIT, and plateletderived growth factor receptor (PDGFR). the blocking of VEGFR and PDGFR may account for the antiangiogenesis effect of sorafenib. Sorafenib contains hydrophilic amide groups, and lipophilic pyridine, and has good biological activity [12] [13] 36] . Sorafenib is characterized by good absorbability because of its small molecular weight and the strong tissue. Its long half-life could reduce intraocular injection times. Additionally, sorafenib is a synthetic urea derivative and the immunogenicity is low [12] [13] 36] . Recent reports have also suggested the role of sorafenib in the treatment of AMD and ROP [15] [16] [17] . Our study focused on the effect of sorafenib on graft survival after corneal transplantation. In comparison of RNA expression, the results of our study show clearly that sorafenib significantly reduced the VEGFR-2 and VEGFR-3 in murine corneas. This is of importance, because VEGFR-2 and 3 in particular plays an important role in the development of lymphatic vessels, and a close linkage between VEGF-C/VEGFR-2 and -3 signaling and corneal graft rejection seems to exist. The sorafenib group showed reduced VEGFR-3 compared with dexamethasone (P=0.051). We suggest that this result can explain the reduced LY in sorafenib group compared with dexamethasone. Sorafenib did not affect VEGF-A compared with DMSO and PBS (P=0.232, 0.087, respectively), resulting in negligible effect on corneal angiogenesis. In our experimental setup, dexamethasone did not affect VEGFR-3 ( Figure 4F ). Dexamethasone mainly affected VEGF-A and VEGFR-2. Dual blockade of VEGFR-2 and another key lymphatic receptor, such as VEGFR-3 by sorafenib, will maximize the anti-lymphangiogenic effect in high risk corneas. In comparison of NV and LY, both sorafenib and dexamethasone showed more pronounced effect in decreasing LY rather than NV in our HRPK model. Moreover, sorafenib decreased LY than dexamethasone. This can explain the results of the enhanced graft survival compared to DMSO only in sorafenib group, not in dexamethasone group. Because LY is a key mediator of corneal transplant rejection, in the high-risk eyes, the rejection rate can be as high as 90% [7] [8] [9] 30, 37] . Unfortunately, many patients who need corneal transplantation fall into this high risk category, and there is little effective treatment for them even with steroid treatment. Our study indicates that sorafenib may be able to replace the effect of steroid in the high-risk grafting beds, to improve the survival rate of high-risk transplants. The antilymphangiogenic effect of sorafenib was significantly higher than that of dexamethasone in HRPK set up in our study (P=0.011), which leads to increased graft survival. Also, our study might support the importance of LY on graft survival rather than hemangiogenesis, which warrants further investigation. In conclusion, we investigated the significant antilymphangiogenic effect of subconjunctivally administered sorafenib (off-label use), a multi-target-receptor tyrosine kinase inhibitor, on increasing transplant survival in a murine high risk keratoplasty model. These results mandate further clinical investigation of sorafenib for corneal graft.
